Lundbeck will be presenting its research at the 2026 Alzheimer’s and Parkinson’s Disease conference
Lundbeck has shared that new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented by Lundbeck with dopamine D1/D2 receptor agonist activity, will be presented at the 2026 Alzheimer’s and Parkinson’s Disease (AD/PD) conference.
The Phase 1b trial evaluated the safety, tolerability, pharmacokinetics, and exploratory clinical activity of orally administered Ly AF28996 in people with advanced Parkinson’s disease.
Results from the trial indicated that Lu AF28996 was generally well tolerated and demonstrated early signals consistent with its proposed mechanism of action, supporting clinical development.
People with advanced Parkinson’s disease experience motor fluctuations, including periods of persistent reduced mobility, despite available treatments. Current pharmacological options may also be associated with treatment-related motor complications, such as dyskinesia, whereas device-aided delivery methods may present practical limitations. These challenges amplify the significance of developing innovative therapies with acceptable tolerability and ease of use for patients with advanced Parkinson’s disease.
Johan Luthman, EVP and head of research and development at Lundbeck, said, “Phase 1b patient trials are an important step in understanding the safety profile and biological activity of new investigational therapies in early clinical development. These data provide supportive evidence to further evaluate the potential of Lu AF28996 in the treatment of people with advanced Parkinson’s disease.”
Lunbeck will also be presenting insights into multiple system atrophy (MSA), a rapidly progressing and fatal neurodegenerative disease for which no approved treatments currently exist.
The data will highlight advances in understanding MSA disease progression and the advantages of Bayesian progression modelling for assessing clinical trial outcomes in MSA.
Presentations will also emphasise the importance of integrating patient perspectives into MSA trial design and of advancing biomarker development to enable earlier diagnosis. These learnings have informed Lundbeck’s amlenetug pivotal program in MSA.
Lu AF28996 and amlenetug are investigational compounds which have not been approved for use by any regulatory authority. The efficacy and safety of both compounds have not been established
